Dynavax Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Dynavax Technologies wird ein Gewinn- und Umsatzwachstum von 42.9% bzw. 18.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 40.5% pro Jahr wachsen soll.

Wichtige Informationen

42.9%

Wachstumsrate der Gewinne

40.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	18.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	05 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

May 22

Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

Jan 31

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Aug 02

Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

Jun 02

We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

May 03

Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Jan 16

Clover, Dynavax COVID-19 vaccine gets EU GMP certificate

Sep 20

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Sep 12

The Alphavaxers: Dynavax And Novavax, 2 Quarters On

Aug 22

Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats

Aug 04

Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Jun 03

Dynavax: Evolving Endemic Situation Adds To Its Risk

May 23

Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

May 12

Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

May 10

Dynavax Technologies: Full Speed Ahead

Mar 01

Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Jan 28

Dynavax: A Coronavirus Growth Story

Jan 17

Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 18

The Momentum Investor: Spotlight On Dynavax Technologies

Oct 25

Dynavax And TLR Biology: Long-Delayed But Outstanding Success

Oct 16

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well

Oct 02

Upgrade: Analysts Just Made A Meaningful Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts

Aug 10

Dynavax: Earnings This Year Ought To Surprise To The Upside

Aug 01

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:DVAX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	407	68	90	99	4
12/31/2025	349	47	55	70	5
12/31/2024	285	19	2	25	5
3/31/2024	236	9	53	56	N/A
12/31/2023	232	-6	96	101	N/A
9/30/2023	361	61	118	122	N/A
6/30/2023	459	111	147	152	N/A
3/31/2023	656	236	134	141	N/A
12/31/2022	723	293	56	63	N/A
9/30/2022	733	320	140	148	N/A
6/30/2022	674	228	142	153	N/A
3/31/2022	470	104	238	247	N/A
12/31/2021	439	72	326	336	N/A
9/30/2021	258	-39	192	199	N/A
6/30/2021	163	-6	101	105	N/A
3/31/2021	113	-62	-31	-27	N/A
12/31/2020	40	-75	-103	-92	N/A
9/30/2020	38	-97	-112	-100	N/A
6/30/2020	35	-138	-115	-94	N/A
3/31/2020	40	-129	-136	-108	N/A
12/31/2019	35	-156	-151	-121	N/A
9/30/2019	30	-159	-161	-132	N/A
6/30/2019	21	-163	-166	-144	N/A
3/31/2019	14	-160	-157	-141	N/A
12/31/2018	8	-159	-146	-131	N/A
9/30/2018	3	-146	-130	-115	N/A
6/30/2018	1	-128	-110	-99	N/A
3/31/2018	0	-109	-93	-82	N/A
12/31/2017	0	-95	N/A	-78	N/A
9/30/2017	8	-89	N/A	-86	N/A
6/30/2017	8	-102	N/A	-97	N/A
3/31/2017	10	-111	N/A	-105	N/A
12/31/2016	11	-112	N/A	-107	N/A
9/30/2016	4	-118	N/A	-103	N/A
6/30/2016	5	-113	N/A	-97	N/A
3/31/2016	4	-108	N/A	-96	N/A
12/31/2015	4	-107	N/A	-93	N/A
9/30/2015	6	-102	N/A	-88	N/A
6/30/2015	7	-102	N/A	-88	N/A
3/31/2015	8	-103	N/A	-87	N/A
12/31/2014	11	-91	N/A	-74	N/A
9/30/2014	12	-90	N/A	-69	N/A
6/30/2014	12	-76	N/A	-58	N/A
3/31/2014	13	-68	N/A	-51	N/A
12/31/2013	11	-75	N/A	-59	N/A
9/30/2013	10	-74	N/A	-54	N/A
6/30/2013	10	-76	N/A	-55	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DVAXDas prognostizierte Gewinnwachstum (42.9% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: DVAXDie Erträge des Unternehmens (42.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: DVAXEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: DVAXDie Einnahmen des Unternehmens (18.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: DVAXDie Einnahmen des Unternehmens (18.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von DVAX in 3 Jahren voraussichtlich hoch sein wird

Dynavax Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024

Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024

Consensus EPS estimates fall by 39%

Consensus estimates of losses per share improve by 49%

Dynavax Technologies Corporation Revises Earnings Guidance for the Full Year 2023

Dynavax Technologies Corporation Reaffirms Revenue Guidance for the Year 2023

Recent updates

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

Dynavax Technologies Corporation Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S

Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain

Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Dynavax Technologies Corporation to Report Q1, 2024 Results on May 08, 2024

Dynavax Technologies Corporation, Annual General Meeting, May 23, 2024

Dynavax: Holding Firm Despite Its Missing Cash Cow

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS exceeds analyst expectations

Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024

Dynavax Technologies Corporation to Report Q4, 2023 Results on Feb 22, 2024

CEO & Director exercised options and sold US$219k worth of stock

Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

Consensus EPS estimates fall by 39%

Insider notifies of intention to sell stock

President & COO notifies of intention to sell stock

Consensus estimates of losses per share improve by 49%

President & COO notifies of intention to sell stock

Dynavax Technologies Corporation Revises Earnings Guidance for the Full Year 2023

Dynavax Technologies Corporation to Report Q3, 2023 Results on Nov 02, 2023

President & COO notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Dynavax Technologies Corporation to Report Q2, 2023 Results on Aug 03, 2023

Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

President & COO recently sold US$191k worth of stock

Dynavax Technologies Corporation Reaffirms Revenue Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

CEO & Director exercised options and sold US$311k worth of stock

Consensus revenue estimates fall by 39%

Full year 2022 earnings: EPS exceeds analyst expectations

Dynavax Technologies Corporation to Report Q4, 2022 Results on Feb 23, 2023

Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Price target decreased to US$22.75

President & COO recently sold US$651k worth of stock

President & COO recently sold US$651k worth of stock

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: US$0.50 (vs US$0.24 loss in 3Q 2021)

Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2022

Dynavax Technologies Corporation to Report Q3, 2022 Results on Nov 03, 2022

Clover, Dynavax COVID-19 vaccine gets EU GMP certificate

Dynavax Technologies Corporation Announces First Participant Dosed in A Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

The Alphavaxers: Dynavax And Novavax, 2 Quarters On

Investor sentiment deteriorated over the past week

Consensus EPS estimates increase by 51%

Insider exercised options and sold US$178k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Dynavax Technologies Corporation Revises Earnings Guidance for the Year 2022

Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats

Now 21% undervalued

Dynavax Technologies Corporation to Report Q2, 2022 Results on Aug 04, 2022

Now 23% undervalued

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Dynavax: Evolving Endemic Situation Adds To Its Risk

Insider exercised options and sold US$60k worth of stock

Investor sentiment improved over the past week

Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

Dynavax Technologies Corporation Reaffirms Earnings Guidance for the Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$27.25